The total return over the past 12 months is +1.41% vs. +17.49% for the S&P 500. So far it's up -7.47% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (0.31%) | +5.55% | +7.16% | +9.70% | +8.92% | +4.93% |
| Total Return CAGR | +1.41% | +7.71% | +9.46% | +12.85% | +12.82% | +9.01% |
| Revenue CAGR | +8.61% | +11.32% | +15.76% | +9.82% | +4.17% | +4.62% |
| Net Income CAGR | +25.93% | +19.23% | +22.61% | +16.75% | +1.64% | +3.29% |
| EPS CAGR | +25.61% | +46.00% | +22.02% | +11.46% | (0.75%) | +4.18% |
| Free Cash Flow CAGR | +6.79% | +10.03% | +14.53% | +20.87% | +0.53% | +1.95% |
| Operating Cash Flow CAGR | +3.15% | +10.70% | +16.46% | +14.11% | +3.10% | +3.45% |
| Dividends CAGR | +2.28% | +3.66% | +2.62% | +1.44% | +1.20% | +4.23% |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
AstraZeneca PLC (AZN)
| Year | Start price | End price | AZN Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $175.50 | $159.64 | (7.47%) | +11.72% | (19.19%) |
| 2025 | $130.00 | $175.50 | +38.01% | +17.72% | +20.29% |
| 2024 | $134.45 | $130.00 | (1.20%) | +24.89% | (26.09%) |
| 2023 | $136.22 | $134.45 | +0.82% | +26.19% | (25.37%) |
| 2022 | $115.85 | $136.22 | +20.46% | (18.17%) | +38.63% |
| 2021 | $101.00 | $115.85 | +17.92% | +28.74% | (10.82%) |
| 2020 | $101.00 | $101.00 | +2.91% | +18.37% | (15.46%) |
| 2019 | $75.96 | $101.00 | +37.39% | +31.22% | +6.17% |
| 2018 | $69.40 | $75.96 | +13.90% | (4.56%) | +18.46% |
| 2017 | $53.87 | $69.40 | +35.18% | +21.70% | +13.48% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
